<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">cRntrKjghYrSKS5KghGv8wH</article-id>
      <article-id pub-id-type="other">00009</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2011000300009</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(11)09600309</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2011005000002</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Suporte ventilat&#243;rio na capacidade funcional de pacientes com insufici&#234;ncia card&#237;aca: estudo piloto</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lima</surname>
            <given-names>Eug&#234;nia da Silva</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cruz</surname>
            <given-names>Cristiano Gon&#231;alves</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Santos</surname>
            <given-names>Fabiane Costa</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gomes-Neto</surname>
            <given-names>Mansueto</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bittencourt</surname>
            <given-names>Hugo Souza</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Reis</surname>
            <given-names>Francisco Jos&#233; Farias Borges dos</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Aras</surname>
            <given-names>Roque</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Guimar&#227;es</surname>
            <given-names>Arm&#234;nio Costa</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rodrigues-Junior</surname>
            <given-names>Erenaldo de Souza</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Salvador</named-content>
          <named-content content-type="state"/>
        </addr-line>
        <institution content-type="orgname">Hospital Ana Nery</institution>
        <institution content-type="orgdiv1">Faculdade Social da Bahia </institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>03</month>
        <year>2011</year>
      </pub-date>
      <volume>96</volume>
      <issue>3</issue>
      <fpage>227</fpage>
      <lpage>232</lpage>
      <history>
        <date date-type="rev-recd">
          <day>21</day>
          <month>05</month>
          <year>2010</year>
        </date>
        <date date-type="received">
          <day>26</day>
          <month>01</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>05</day>
          <month>07</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: A insufici&#234;ncia card&#237;aca &#233; um importante problema de sa&#250;de p&#250;blica, apresentando a dispneia e a fadiga como principais sintomas cl&#237;nicos. A utiliza&#231;&#227;o do suporte ventilat&#243;rio n&#227;o invasivo vem atuando como coadjuvante da reabilita&#231;&#227;o card&#237;aca na tentativa de melhorar a capacidade funcional dos pacientes. OBJETIVO: Avaliar a capacidade funcional de pacientes com insufici&#234;ncia card&#237;aca submetidos ao suporte ventilat&#243;rio. M&#201;TODOS: Foram avaliados dados sociodemogr&#225;ficos, qualidade de vida, FC, press&#227;o arterial (PA), satura&#231;&#227;o perif&#233;rica de oxig&#234;nio (SpO2), dispneia, concentra&#231;&#227;o de lactato, antes e depois do teste de caminhada de 6 minutos, e a dist&#226;ncia percorrida de pacientes com insufici&#234;ncia card&#237;aca cr&#244;nica (ICC), de ambos os sexos, com fra&#231;&#227;o FEVE &lt; 45,0%, randomizados em dois grupos: controle e CPAP (utilizou CPAP 10 cmH2O por 30 minutos). RESULTADOS: Participaram 12 pacientes com ICC classe funcional II e III (NYHA), com m&#233;dia de fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo (FEVE, %) de 35,3 &#177; 8,7, sendo que 8 eram do sexo masculino. A m&#233;dia de idade foi de 46,3 &#177; 10,3 anos. Na compara&#231;&#227;o entre os grupos Controle e CPAP, no final do 6&#186; min, foi encontrada diferen&#231;a significativa nos valores de SpO2% entre os grupos (Controle: 93,6 &#177; 1,5 % vs CPAP: 96,1 &#177; 1,8%; p = 0,027), dispneia (Controle: 13,1 &#177; 1,16 vs CPAP: 11 &#177; 0,8; p = 0,009), concentra&#231;&#227;o de lactato (Controle: 3,3 &#177; 0,7 mmol/l vs CPAP: 2,3 &#177; 0,5 mmol/l; p = 0,025), e dist&#226;ncia percorrida no TC6 (Controle: 420,6 &#177; 73,8 m vs CPAP: 534 &#177; 89,91 m; p = 0,038). CONCLUS&#195;O: A realiza&#231;&#227;o pr&#233;via do CPAP apresentou efeitos ben&#233;ficos na SpO2, na dispneia, na concentra&#231;&#227;o de lactato, no duplo produto e na dist&#226;ncia percorrida no TC6 de pacientes com ICC na realiza&#231;&#227;o do TC6.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Insufici&#234;ncia card&#237;aca</kwd>
        <kwd>reabilita&#231;&#227;o card&#237;aca</kwd>
        <kwd>assist&#234;ncia ao paciente</kwd>
        <kwd>capacidade vital</kwd>
        <kwd>respira&#231;&#227;o artificial</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>07</day>
        <month>01</month>
        <year>2011</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>Suporte ventilat&#243;rio na capacidade funcional de pacientes com insufici&#234;ncia card&#237;aca: estudo piloto</p>
    <p>
      <bold>Eug&#234;nia da Silva Lima; Cristiano Gon&#231;alves Cruz; Fabiane Costa Santos; Mansueto Gomes-Neto; Hugo Souza Bittencourt; Francisco Jos&#233; Farias Borges dos Reis; Roque Aras; Arm&#234;nio Costa Guimar&#227;es; Erenaldo de Souza Rodrigues-Junior</bold>
    </p>
    <p> Faculdade Social da Bahia, Hospital Ana Nery, Salvador, BA - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="nt">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> A insufici&#234;ncia card&#237;aca &#233; um importante problema de sa&#250;de p&#250;blica, apresentando a dispneia e a fadiga como principais sintomas cl&#237;nicos. A utiliza&#231;&#227;o do suporte ventilat&#243;rio n&#227;o invasivo vem atuando como coadjuvante da reabilita&#231;&#227;o card&#237;aca na tentativa de melhorar a capacidade funcional dos pacientes. </p>
    <p><bold>OBJETIVO:</bold> Avaliar a capacidade funcional de pacientes com insufici&#234;ncia card&#237;aca submetidos ao suporte ventilat&#243;rio. </p>
    <p><bold>M&#201;TODOS:</bold> Foram avaliados dados sociodemogr&#225;ficos, qualidade de vida, FC, press&#227;o arterial (PA), satura&#231;&#227;o perif&#233;rica de oxig&#234;nio (SpO<sub>2</sub>), dispneia, concentra&#231;&#227;o de lactato, antes e depois do teste de caminhada de 6 minutos, e a dist&#226;ncia percorrida de pacientes com insufici&#234;ncia card&#237;aca cr&#244;nica (ICC), de ambos os sexos, com fra&#231;&#227;o FEVE <underline>&lt;</underline> 45,0%, randomizados em dois grupos: controle e CPAP (utilizou CPAP 10 cmH<sub>2</sub>O por 30 minutos). </p>
    <p><bold>RESULTADOS:</bold> Participaram 12 pacientes com ICC classe funcional II e III (NYHA), com m&#233;dia de fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo (FEVE, %) de 35,3 &#177; 8,7, sendo que 8 eram do sexo masculino. A m&#233;dia de idade foi de 46,3 &#177; 10,3 anos. Na compara&#231;&#227;o entre os grupos Controle e CPAP, no final do 6&#186; min, foi encontrada diferen&#231;a significativa nos valores de SpO<sub>2</sub>% entre os grupos (Controle: 93,6 &#177; 1,5 % <italic>vs</italic> CPAP: 96,1 &#177; 1,8%; p = 0,027), dispneia (Controle: 13,1 &#177; 1,16 <italic>vs</italic> CPAP: 11 &#177; 0,8; p = 0,009), concentra&#231;&#227;o de lactato (Controle: 3,3 &#177; 0,7 mmol/l <italic>vs</italic> CPAP: 2,3 &#177; 0,5 mmol/l; p = 0,025), e dist&#226;ncia percorrida no TC6 (Controle: 420,6 &#177; 73,8 m <italic>vs</italic> CPAP: 534 &#177; 89,91 m; p = 0,038). </p>
    <p><bold>CONCLUS&#195;O: </bold> A realiza&#231;&#227;o pr&#233;via do CPAP apresentou efeitos ben&#233;ficos na SpO<sub>2</sub>, na dispneia, na concentra&#231;&#227;o de lactato, no duplo produto e na dist&#226;ncia percorrida no TC6 de pacientes com ICC na realiza&#231;&#227;o do TC6.</p>
    <p><bold>Palavras-chave:</bold> Insufici&#234;ncia card&#237;aca, reabilita&#231;&#227;o card&#237;aca, assist&#234;ncia ao paciente, capacidade vital, respira&#231;&#227;o artificial.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A insufici&#234;ncia card&#237;aca (IC) constitui atualmente um importante problema de sa&#250;de p&#250;blica<sup>1</sup>, apresentando a dispneia e a fadiga durante o exerc&#237;cio ou atividades de vida di&#225;ria como principais sintomas cl&#237;nicos, sendo a maior causa para os pacientes interromperem o esfor&#231;o f&#237;sico precocemente, causando restri&#231;&#227;o das atividades cotidianas e consequente limita&#231;&#227;o na capacidade funcional<sup>2,3</sup>.</p>
    <p>A progress&#227;o dos sintomas da IC gera uma diminui&#231;&#227;o do n&#237;vel de atividade f&#237;sica, provocando o descondicionamento f&#237;sico, que contribui para elevar ainda mais os sintomas e a intoler&#226;ncia ao exerc&#237;cio, reduzindo progressivamente a capacidade funcional, o que acarreta uma condi&#231;&#227;o cl&#237;nica frequente, de alto custo, geralmente incapacitante e com mortalidade elevada<sup>4</sup>.</p>
    <p>No &#226;mbito da reabilita&#231;&#227;o card&#237;aca (RC), busca-se o condicionamento do indiv&#237;duo, tendo como objetivo a melhoria da capacidade funcional e o retorno &#224;s atividades de trabalho e sociais, nas quais o desempenho f&#237;sico &#233; um fator limitante<sup>5,6</sup>. Um dos principais agravos &#233; o desenvolvimento da insufici&#234;ncia respirat&#243;ria aguda devido &#224; redu&#231;&#227;o da complac&#234;ncia pulmonar que aumenta o trabalho respirat&#243;rio<sup>7</sup>. Tal redu&#231;&#227;o &#233; resultado da insufici&#234;ncia circulat&#243;ria causada pela disfun&#231;&#227;o do ventr&#237;culo esquerdo (VE), que pode causar preju&#237;zos agudos e/ou cr&#244;nicos na fun&#231;&#227;o respirat&#243;ria<sup>8</sup>.</p>
    <p>Nesse cen&#225;rio, surge a utiliza&#231;&#227;o do suporte ventilat&#243;rio n&#227;o invasivo (SVNI) como coadjuvante da reabilita&#231;&#227;o card&#237;aca na tentativa de melhorar a capacidade funcional dos pacientes, uma vez que o SVNI reduz o trabalho respirat&#243;rio, melhora a oxigena&#231;&#227;o, aumenta a complac&#234;ncia pulmonar associada &#224; melhora do volume ejetado, devido ao aumento da press&#227;o intrator&#225;cica<sup>9</sup>.</p>
    <p>A utiliza&#231;&#227;o do SVNI tem sido uma alternativa na tentativa de aumentar a oxigena&#231;&#227;o arterial e proporcionar uma melhor toler&#226;ncia durante o exerc&#237;cio f&#237;sico devido a sua sens&#237;vel atua&#231;&#227;o na intera&#231;&#227;o cardiorrespirat&#243;ria, proporcionando uma melhor resposta card&#237;aca e respirat&#243;ria durante o exerc&#237;cio. Entretanto, s&#227;o escassos os estudos que levam em considera&#231;&#227;o a utiliza&#231;&#227;o do SVNI associado ou n&#227;o ao exerc&#237;cio na IC no contexto da RC<sup>10</sup>. </p>
    <p>Sendo assim, a proposta do presente estudo foi avaliar a capacidade funcional de pacientes com IC submetidos ao SVNI.</p>
    <p>
      <bold>Metodologia</bold>
    </p>
    <p>Foram avaliados pacientes de ambos os sexos, com diagn&#243;stico de ICC (classe funcional II e III da <italic>New York Heart Association - NYHA</italic>) encaminhados para o setor de Ergoespirometria e Reabilita&#231;&#227;o Cardiovascular do Hospital Ana Nery - UFBA. Neste estudo, foram inclu&#237;dos pacientes com fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo (FEVE) <underline>&lt;</underline> 45,0% (determinado por ecocardiografia), idade superior a 18 anos, conscientes e neurologicamente capazes de se comunicarem e se locomoverem. Foram exclu&#237;dos os pacientes que apresentaram limita&#231;&#227;o da atividade f&#237;sica por fatores diferentes de dispneia de esfor&#231;o e fadiga, tais como claudica&#231;&#227;o intermitente, artrose e artrite de membros inferiores, doen&#231;a psiqui&#225;trica, doen&#231;a orovalvular reum&#225;tica, anemia, doen&#231;a pulmonar obstrutiva cr&#244;nica (DPOC), qualquer estado febril ou doen&#231;a infecciosa, ou que apresentasse intoler&#226;ncia ao SVNI.</p>
    <p>Inicialmente, foi realizada uma entrevista para coleta de dados da caracteriza&#231;&#227;o da amostra levando-se em considera&#231;&#227;o o manejo da IC, dentre eles o g&#234;nero, &#237;ndice de massa corporal (IMC), press&#227;o arterial (PA) e a classifica&#231;&#227;o funcional de acordo com a <italic>NYHA</italic>.</p>
    <p>Na sequ&#234;ncia, foi aplicado o question&#225;rio para a verifica&#231;&#227;o da qualidade de vida (QV) Minnesota (<italic>Minnesota Living with Heart Failure Questionnaire</italic>), uma medida doen&#231;a-espec&#237;fica que avalia as percep&#231;&#245;es dos pacientes sobre a influ&#234;ncia da IC nos aspectos f&#237;sicos, socioecon&#244;micos e psicol&#243;gicos<sup>11</sup>. </p>
    <p>Outra importante considera&#231;&#227;o sobre esse instrumento &#233; seu formato abrangente, f&#225;cil de aplicar e o fato de ter sido validado para a popula&#231;&#227;o brasileira<sup>12</sup>. Os participantes responderam os 21 itens usando uma escala de resposta de 6 pontos (0-5). O resumo do escore total (escore global) pode variar de 0 a 105; um escore mais baixo reflete melhor QV. Os escores nas tr&#234;s subescalas (dimens&#245;es) refletem dificuldades f&#237;sicas (quest&#245;es n&#186;. 2, 3, 4, 5, 6, 7, 12 e 13), emocionais (quest&#245;es n&#186;. 17, 18, 19, 20 e 21) e os outros itens est&#227;o relacionados a considera&#231;&#245;es financeiras, efeitos colaterais de medicamentos e estilo de vida (dimens&#245;es gerais).</p>
    <p>Posteriormente, os pacientes foram alocados em dois grupos de forma randomizada por sorteio, onde foram colocadas tarjas azuis e vermelhas em envelopes opacos. Os pacientes que retiravam o envelope com tarja azul seriam alocados no grupo CPAP, que realizou a aplica&#231;&#227;o de CPAP a 10 cmH<sub>2</sub>O por 30 minutos, antes do teste de caminhada de 6 minutos (TC6), e os que retiraram tarja vermelha foram alocados no grupo Controle, que n&#227;o realizou CPAP. Os pacientes n&#227;o tinham conhecimento de quem havia realizado CPAP, pois os grupos realizavam os procedimentos em dias distintos.</p>
    <p>Foi coletada uma amostra de sangue capilar do dedo indicador da m&#227;o direita do examinado, com as lancetas est&#233;reis e descart&#225;veis da marca Accu-Chek<sup>&#174;</sup> Softclix<sup>&#174;</sup> Pro (Roche, Alemanha), ap&#243;s 10 minutos de repouso na posi&#231;&#227;o sentada antes do TC6 (para o grupo CPAP, antes da realiza&#231;&#227;o da CPAP) e no final do 6&#186; minuto do TC6, e dosado sua concentra&#231;&#227;o de lactato utilizando o Lact&#237;metro Accutrend<sup>&#174;</sup> (Roche, Alemanha). </p>
    <p>O TC6 foi realizado de acordo com os crit&#233;rios estabelecidos pela <italic>American Toracic Society</italic> (<italic>ATS</italic>)<sup>13 </sup>e as diretrizes para realiza&#231;&#227;o de exames ergom&#233;tricos da Sociedade Brasileira de Cardiologia (SBC)<sup>14</sup>, em pista de 30 metros de comprimento, sem acompanhamento e recebendo apenas as orienta&#231;&#245;es padronizadas a cada minuto. Os pacientes foram monitorados quanto &#224; frequ&#234;ncia card&#237;aca (FC, bpm), press&#227;o arterial (PA, mmHg), satura&#231;&#227;o perif&#233;rica de oxig&#234;nio (SpO<sub>2</sub>, %), sensa&#231;&#227;o subjetiva de dispneia (escala de Borg)<sup>15</sup>, sendo registrados os valores de repouso e nos 2&#186;, 4&#186; e 6&#186; minutos. </p>
    <p>A pesquisa contou com o pr&#233;vio consentimento dos pacientes e foi aprovada pelo Comit&#234; de &#201;tica e Pesquisa do Hospital Ana Nery - UFBA, sob parecer n&#186; 37/09.</p>
    <p>Para an&#225;lise dos dados demogr&#225;ficos e cl&#237;nicos, foram utilizadas estat&#237;sticas descritivas e de frequ&#234;ncia; para normalidade e homogeneidade das vari&#225;veis foi utilizado o teste de Shapiro-Wilk com o uso do <italic>software SPSS</italic> (<italic>Statistical Package for the Social Sciences</italic>) <italic>for Windows</italic> (vers&#227;o 13.0). O teste t de <italic>Student</italic> foi utilizado para os dados param&#233;tricos e para as vari&#225;veis com distribui&#231;&#227;o n&#227;o param&#233;trica. O teste Wilcoxon foi utilizado para comparar as diferen&#231;as das m&#233;dias intragrupos. Na compara&#231;&#227;o entre os grupos, foram utilizados para os dados param&#233;tricos o teste t de <italic>Student</italic> para amostras independentes e o teste de Mann-Whitney para os dados n&#227;o param&#233;tricos. Foi estabelecido um n&#237;vel de signific&#226;ncia de 5,0%.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>Participaram deste estudo 12 pacientes com ICC classe funcional II e III NYHA, com m&#233;dia de FEVE% de 35,3 &#177; 8,7, sendo 8 do sexo masculino. A m&#233;dia de idade foi de 46,3 &#177; 10,3 anos e o foi IMC de 25,1 &#177; 5,5 kg/m<sup>2</sup>. Os dados da caracteriza&#231;&#227;o cl&#237;nica dos sujeitos estudados est&#227;o apresentados na <xref ref-type="table" rid="tab01">Tabela 1</xref>.</p>
    <table-wrap id="tab01">
      <graphic xlink:href="1678-4170-abc-96-03-0227-00002-gt01.jpg"/></table-wrap>
    <p>A <xref ref-type="table" rid="tab02">Tabela 2</xref> apresenta a compara&#231;&#227;o das caracter&#237;sticas cl&#237;nicas dos pacientes por grupo (grupo Controle <italic>vs</italic> grupo CPAP), onde n&#227;o foi observada diferen&#231;a significativa para as vari&#225;veis estudadas entre os grupos. </p>
    <table-wrap id="tab02">
      <graphic xlink:href="1678-4170-abc-96-03-0227-00002-gt02.jpg"/></table-wrap>
    <p>No grupo controle, quando comparado as vari&#225;veis em repouso com o 6&#186; minuto, foi observada uma diferen&#231;a significativa para as vari&#225;veis hemodin&#226;micas (PAS 126,6 &#177; 8,1 mmHg <italic>vs</italic> 150 &#177; 8,9 mmHg, com p = 0,003; PAD 85 &#177; 10,4 mmHg <italic>vs</italic> 105 &#177; 5,4 mmHg, com p = 0,01 e FC 81,1 &#177; 166,8 bpm <italic>vs</italic> 117,8 &#177; 19,3 bpm, com p = 0,006). Na an&#225;lise das vari&#225;veis respirat&#243;rias e metab&#243;licas, foi observada uma diferen&#231;a significativa em SpO<sub>2</sub> 97,3 &#177; 1% <italic>vs</italic> 93,6 &#177; 1,5%, p = 0,001; dispneia 7 &#177; 1,26 <italic>vs</italic> 13,1 &#177; 1,16, com p = 0,000 e a concentra&#231;&#227;o de lactato 1,6 &#177; 0,73 mmol/l <italic>vs</italic> 3,3 &#177; 0,7 mmol/l, p = 0,028 (<xref ref-type="table" rid="tab03">Tabela 3</xref>).</p>
    <table-wrap id="tab03">
      <graphic xlink:href="1678-4170-abc-96-03-0227-00002-gt03.jpg"/></table-wrap>
    <p>Quando comparado as vari&#225;veis em repouso com o 6&#186; min no grupo CPAP, houve tamb&#233;m diferen&#231;a significativa nos dados hemodin&#226;micos (PAS 120 &#177; 15,4 mmHg <italic>vs</italic> 140 &#177; 12,6 mmHg, com p = 0,001; PAD 76,6 &#177; 8,1 mmHg <italic>vs</italic> 101,6 &#177; 13,2 mmHg, com p = 0,002 e FC 73,1 &#177; 7,6 bpm <italic>vs</italic> 99,6 &#177; 13 bpm, com p = 0,001). Na an&#225;lise das vari&#225;veis respirat&#243;rias e metab&#243;licas, foi observada uma diferen&#231;a significativa em dispneia 6,6 &#177; 0,8 <italic>vs</italic> 11 &#177; 0,8, com p = 0,001 e na concentra&#231;&#227;o de Lactato 1,1 &#177; 0,2 mmol/l <italic>vs</italic> 2,3 &#177; 0,5 mmol/l, p = 0,028. No entanto, na avalia&#231;&#227;o da SpO<sub>2, </sub>n&#227;o foi observada diferen&#231;a significativa entre o momento em repouso e o 6&#186; min (97,5 &#177; 1,% <italic>vs</italic> 96,1 &#177; 1,8%, p = 0,286), conforme <xref ref-type="table" rid="tab04">Tabela 4</xref>.</p>
    <table-wrap id="tab04">
      <graphic xlink:href="1678-4170-abc-96-03-0227-00002-gt04.jpg"/></table-wrap>
    <p>Na an&#225;lise comparativa entre os grupos Controle e CPAP no final do 6&#186; minuto, foi encontrada diferen&#231;a significativa nos valores de SpO<sub>2</sub>% (Controle: 93,6 &#177; 1,5 % <italic>vs</italic> CPAP: 96,1 &#177; 1,8%; p = 0,027), dispneia (Controle: 13,1 &#177; 1,16 <italic>vs</italic> CPAP: 11 &#177; 0,8; p = 0,009), concentra&#231;&#227;o de lactato (Controle: 3,3 &#177; 0,7 mmol/l <italic>vs</italic> CPAP: 2,3 &#177; 0,5 mmol/l; p = 0,025), duplo-produto (Controle: 17.758,3 &#177; 3.623 mmHg.bpm <italic>vs</italic> CPAP: 14.035 &#177; 2.859 mmHg.bpm; p = 0,038) e dist&#226;ncia percorrida no TC6 (Controle: 420,6 &#177; 73,8 m <italic>vs</italic> CPAP: 534 &#177; 89,91 m; p = 0,038).</p>
    <p>Foi observada ainda uma diferen&#231;a nos dados hemodin&#226;micos, no entanto, sem signific&#226;ncia estat&#237;stica, conforme <xref ref-type="table" rid="tab05">Tabela 5</xref>. </p>
    <table-wrap id="tab05">
      <graphic xlink:href="1678-4170-abc-96-03-0227-00002-gt05.jpg"/></table-wrap>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>Por interm&#233;dio do presente estudo, podemos observar que os pacientes submetidos ao SVNI obtiveram melhores resultados, ressaltando uma maior dist&#226;ncia percorrida no TC6 e consequente melhor capacidade funcional<sup>16</sup>.</p>
    <p>A IC apresenta consequ&#234;ncias multissist&#234;micas que afetam diretamente a capacidade funcional dos pacientes e, consequentemente, as suas atividades de vida di&#225;ria, bem como sua QV<sup>17</sup>. Isso foi corroborado com os resultados do presente estudo.</p>
    <p>A RC &#233; considerada um conjunto de terap&#234;uticas multidisciplinares que objetivam a melhor evolu&#231;&#227;o cl&#237;nica, do ponto de vista f&#237;sico e psicossocial. Durante o processo de reabilita&#231;&#227;o, os pacientes realizam diversos exerc&#237;cios sob a supervis&#227;o da equipe multiprofissional. Dentre os principais exerc&#237;cios realizados no tratamento desses pacientes, temos a caminhada, que apresenta, como principal caracter&#237;stica, sua f&#225;cil compreens&#227;o e realiza&#231;&#227;o por parte dos pacientes<sup>18</sup>.</p>
    <p>A realiza&#231;&#227;o da caminhada &#233; limitada nos pacientes portadores de IC por diversos fatores cl&#237;nicos, como por exemplo, perda de fibras tipo I na musculatura esquel&#233;tica, hipotrofia muscular, condi&#231;&#227;o hemodin&#226;mica pr&#233;via e anormalidades metab&#243;licas<sup>19</sup>. Al&#233;m disso, trabalhos recentes v&#234;m mostrando os comprometimentos na fun&#231;&#227;o respirat&#243;ria, como diminui&#231;&#227;o da for&#231;a muscular respirat&#243;ria, congest&#227;o pulmonar, aumento da resist&#234;ncia pulmonar com limita&#231;&#227;o ao fluxo de ar e preju&#237;zo no processo da ventila&#231;&#227;o<sup>20</sup>.</p>
    <p>Schroeder e cols.<sup>21</sup>, em 2003, avaliaram o n&#237;vel de limita&#231;&#227;o ao fluxo a&#233;reo em indiv&#237;duos sadios e em pacientes com IC. Nesse trabalho, foi encontrada uma limita&#231;&#227;o ao fluxo a&#233;reo em repouso nos pacientes com IC, que foi ainda mais exacerbada durante a realiza&#231;&#227;o do exerc&#237;cio. </p>
    <p>O SVNI, por utilizar press&#227;o positiva, consegue otimizar a fun&#231;&#227;o card&#237;aca e respirat&#243;ria dos pacientes com IC. A press&#227;o positiva diminui as grandes varia&#231;&#245;es na press&#227;o pleural e, consequentemente, reduz a press&#227;o transmural do VE, melhorando o desempenho contr&#225;til do cora&#231;&#227;o<sup>22</sup>.</p>
    <p>Atrav&#233;s dos dados, n&#227;o evidenciamos nos par&#226;metros hemodin&#226;micos (PAS, PAD e FC) efeitos significativos da realiza&#231;&#227;o pr&#233;via da press&#227;o positiva, em compara&#231;&#227;o com o grupo controle ao final do 6&#186; minuto. Tal condi&#231;&#227;o talvez se deva ao fato de que, durante a realiza&#231;&#227;o do exerc&#237;cio, os pacientes n&#227;o faziam mais uso da press&#227;o positiva<sup>23</sup>. No entanto, na avalia&#231;&#227;o do duplo-produto ao final do exerc&#237;cio, encontramos menores valores desse par&#226;metro fisiol&#243;gico no grupo de pacientes que fizeram uso do SVNI. Essa condi&#231;&#227;o nos leva a crer que o SVNI consegue melhorar previamente o desempenho do sistema cardiovascular e do sistema respirat&#243;rio de tal forma que, durante a realiza&#231;&#227;o do TC6, tais pacientes apresentavam um menor trabalho card&#237;aco<sup>22</sup>.</p>
    <p>Concordando com os achados do presente estudo, Chermont e cols.<sup>10</sup>, estudaram 12 pacientes, divididos em grupo placebo e grupo CPAP por 30 minutos antes da realiza&#231;&#227;o do TC6. Nesse estudo, os autores n&#227;o encontraram altera&#231;&#245;es significantes nos dados de PAS, PAD e press&#227;o arterial m&#233;dia (PAM).</p>
    <p>J&#225; em rela&#231;&#227;o &#224; fun&#231;&#227;o pulmonar, por diminuir a resist&#234;ncia de via a&#233;rea nos paciente com IC, a press&#227;o positiva aumenta a complac&#234;ncia pulmonar, melhora a troca gasosa, diminui o trabalho respirat&#243;rio e reduz a limita&#231;&#227;o ao fluxo a&#233;reo<sup>24</sup>. No mesmo sentido, os nossos resultados mostraram que a realiza&#231;&#227;o pr&#233;via do CPAP por 30 minutos otimizou a fun&#231;&#227;o pulmonar dos pacientes de tal forma que estes, ao final do 6&#186; minuto de caminhada, n&#227;o apresentaram uma dessatura&#231;&#227;o significante. </p>
    <p>Na an&#225;lise comparativa dos par&#226;metros estudados ao final do 6&#186; minuto, observamos um maior n&#237;vel de SpO<sub>2 </sub>e menor &#237;ndice de dispneia no grupo que fez uso pr&#233;vio do CPAP, mostrando que os efeitos ben&#233;ficos da press&#227;o positiva, na fun&#231;&#227;o pulmonar dos pacientes com IC, perduraram at&#233; o final do exerc&#237;cio proposto neste estudo. Tais resultados demonstram a capacidade da ventila&#231;&#227;o n&#227;o invasiva em melhorar os par&#226;metros da fun&#231;&#227;o pulmonar, e desta forma, possibilitar a realiza&#231;&#227;o do exerc&#237;cio de maneira mais eficaz.</p>
    <p>Barbas e cols.<sup>25</sup> relatam os efeitos positivos da press&#227;o positiva na fun&#231;&#227;o pulmonar de pacientes cardiopatas com diminui&#231;&#227;o da congest&#227;o pulmonar e melhora da troca gasosa.</p>
    <p>Witmmer e cols.<sup>26</sup> utilizaram diariamente o CPAP por 30 minutos antes da realiza&#231;&#227;o de exerc&#237;cio para pacientes com IC por duas semanas, sendo observado que houve uma melhora na fun&#231;&#227;o pulmonar e na dist&#226;ncia percorrida dos pacientes que utilizaram CPAP, concordando com os resultados encontrados no presente estudo. </p>
    <p>Atrav&#233;s da an&#225;lise simplificada da concentra&#231;&#227;o de lactato, pudemos constatar que os pacientes submetidos ao SVNI obtiveram menores concentra&#231;&#245;es de lactato, sugerindo uma menor utiliza&#231;&#227;o de metabolismo anaer&#243;bico. Evid&#234;ncias cient&#237;ficas atuais demonstram a rela&#231;&#227;o entre o metabolismo anaer&#243;bico e a capacidade funcional como importante preditor de mortalidade<sup>27,28</sup>.</p>
    <p>O presente estudo apresentou algumas limita&#231;&#245;es. Inicialmente, n&#227;o foi poss&#237;vel definir o tempo de dura&#231;&#227;o dos efeitos verificados, uma vez que a administra&#231;&#227;o do SVNI foi interrompida para a realiza&#231;&#227;o do TC6. Seria importante determinar se v&#225;rias sess&#245;es com o uso do SVNI poderiam ser capazes de manter o efeito por um tempo mais prolongado e se estes efeitos est&#227;o associados com uma melhora cl&#237;nica.</p>
    <p>Sendo assim, a continuidade deste estudo, com aumento da amostra, bem como a realiza&#231;&#227;o de outras pesquisas nesta tem&#225;tica, torna-se necess&#225;ria para elucidar os efeitos do SVNI como uma nova alternativa de suporte terap&#234;utico na RC de pacientes com IC.</p>
    <p>
      <bold>Conclus&#227;o</bold>
    </p>
    <p>A realiza&#231;&#227;o pr&#233;via do CPAP com 10 cmH<sub>2</sub>O por 30 minutos apresentou efeitos ben&#233;ficos na SpO<sub>2</sub>, no &#237;ndice de dispneia, na concentra&#231;&#227;o de lactato, no duplo-produto e na dist&#226;ncia percorrida de pacientes com ICC na realiza&#231;&#227;o do TC6. Por&#233;m, esses resultados devem ser observados com cautela, pois esta pesquisa se trata de um estudo-piloto realizado com uma amostra reduzida de pacientes.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="nt" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Eugenia da Silva Lima </p>
        <p> Conj Colinas de Periperi Bl 19 Apt 302 - Periperi </p>
        <p> 40725-430 - Salvador, BA - Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="eugenia79@ibest.com.br">eugenia79@ibest.com.br</email>
        </p>
      </fn>
    </p>
    <p> Artigo recebido em 26/01/10; revisado recebido em 21/05/10; aceito em 05/07/10.</p>
    <p>Full texts in English - <ext-link ext-link-type="uri" xlink:href="http://www.arquivosonline.com.br">http://www.arquivosonline.com.br</ext-link></p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Barreto ACP, Del Carlo CH, Cardoso JN, Morgado PC, Munhoz RT, Ochiai ME, et al. Re-hospitaliza&#231;&#245;es e morte por insufici&#234;ncia card&#237;aca: &#237;ndices ainda alarmantes. Arq Bras Cardiol. 2008; 91 (5): 335-41.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Re-hospitaliza&#231;&#245;es e morte por insufici&#234;ncia card&#237;aca: &#237;ndices ainda alarmantes</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>335</fpage>
          <lpage>41</lpage>
          <issue>5</issue>
          <volume>91</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Barreto</surname>
              <given-names>ACP</given-names>
            </name>
            <name>
              <surname>Del Carlo</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Cardoso</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Morgado</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Munhoz</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Ochiai</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Figueroa MS, Peters JI. Congestive heart failure: diagnosis, pathophysiology, therapy, and implications for respiratory care. Respir Care. 2006; 51 (4): 403-12.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Congestive heart failure: diagnosis, pathophysiology, therapy, and implications for respiratory care</article-title>
          <source>Respir Care</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>403</fpage>
          <lpage>12</lpage>
          <issue>4</issue>
          <volume>51</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Figueroa</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>JI</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Francis GS. Pathophysiology of chronic heart failure. Am J Med. 2001; 110 (Suppl 7A): 37S-46S.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Pathophysiology of chronic heart failure</article-title>
          <source>Am J Med</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>37S</fpage>
          <lpage>46S</lpage>
          <volume>110</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Francis</surname>
              <given-names>GS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Guimar&#227;es JI, Mesquita ET, Bocchi EA, Vilas-Boas F, Montera MW, Batlouni M. / Sociedade Brasileira de Cardiologia. Revis&#227;o das II Diretrizes para o diagn&#243;stico e tratamento da insufici&#234;ncia card&#237;aca. Arq Bras Cardiol. 2002; 79 (4): 1-30.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Revis&#227;o das II Diretrizes para o diagn&#243;stico e tratamento da insufici&#234;ncia card&#237;aca</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1</fpage>
          <lpage>30</lpage>
          <issue>4</issue>
          <volume>79</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Guimar&#227;es</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Mesquita</surname>
              <given-names>ET</given-names>
            </name>
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Vilas-Boas</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Montera</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Batlouni</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Bocchi EA, Vilas-Boas F, Perrone S, Caama&#241;o AG, Clausell N, Moreira M da C, et al. I Latin American Guidelines for the Assessment and Management of Decompensated Heart Failure. Arq Bras Cardiol. 2005; 85 (Suppl.3): 1-48.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>I Latin American Guidelines for the Assessment and Management of Decompensated Heart Failure</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1</fpage>
          <lpage>48</lpage>
          <volume>85</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Vilas-Boas</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Perrone</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Caama&#241;o</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Clausell</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Moreira</surname>
              <given-names>M da C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Levigner I, Bronks R, Cody DV, Linton I, Davie A. The effect of resistance training on left ventricular function and structure of patients with chronic heart failure. Int J Cardiol. 2005; 105 (2): 159-63.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The effect of resistance training on left ventricular function and structure of patients with chronic heart failure</article-title>
          <source>Int J Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>159</fpage>
          <lpage>63</lpage>
          <issue>2</issue>
          <volume>105</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Levigner</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Bronks</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cody</surname>
              <given-names>DV</given-names>
            </name>
            <name>
              <surname>Linton</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Davie</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Andrade JP, Montera MW, Almeida DR, Tinoco EM, Rocha RM, Moura LAZ, et al. / Sociedade Brasileira de Cardiologia. II Diretriz brasileira de insufici&#234;ncia card&#237;aca aguda. Arq Bras Cardiol. 2009; 93 (3 supl.3): 1-65.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>II Diretriz brasileira de insufici&#234;ncia card&#237;aca aguda</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>1</fpage>
          <lpage>65</lpage>
          <issue>3</issue>
          <volume>93</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Andrade</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Montera</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Tinoco</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Rocha</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Moura</surname>
              <given-names>LAZ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Barreto ACP, Ramires JAF. Insufici&#234;ncia card&#237;aca. Arq Bras Cardiol. 1998; 71 (4): 635-42.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Insufici&#234;ncia card&#237;aca</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>635</fpage>
          <lpage>42</lpage>
          <issue>4</issue>
          <volume>71</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Barreto</surname>
              <given-names>ACP</given-names>
            </name>
            <name>
              <surname>Ramires</surname>
              <given-names>JAF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Naughton MT, Liu PP, Bernard DC, Goldstein RS, Bradley TD. Treatment of congestive heart failure and Cheyne-Stokes respiration during sleep by continuous positive airway pressure. Am J Respir Crit Care Med. 1995; 151 (1): 92-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Treatment of congestive heart failure and Cheyne-Stokes respiration during sleep by continuous positive airway pressure</article-title>
          <source>Am J Respir Crit Care Med</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>92</fpage>
          <lpage>7</lpage>
          <issue>1</issue>
          <volume>151</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Naughton</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>PP</given-names>
            </name>
            <name>
              <surname>Bernard</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Goldstein</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Bradley</surname>
              <given-names>TD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Chermont S, Quint&#227;o MM, Mesquita ET, Rocha NN, N&#243;brega AC. Noninvasive ventilation with continuous positive airway pressure acutely improves 6-minute walk distance in chronic heart failure. J Cardiopulm Rehabil Prev. 2009; 29 (1): 44-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Noninvasive ventilation with continuous positive airway pressure acutely improves 6-minute walk distance in chronic heart failure</article-title>
          <source>J Cardiopulm Rehabil Prev</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>44</fpage>
          <lpage>8</lpage>
          <issue>1</issue>
          <volume>29</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Chermont</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Quint&#227;o</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Mesquita</surname>
              <given-names>ET</given-names>
            </name>
            <name>
              <surname>Rocha</surname>
              <given-names>NN</given-names>
            </name>
            <name>
              <surname>N&#243;brega</surname>
              <given-names>AC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living With Heart Failure Questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Am Heart J. 1992; 124 (4): 1017-25.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Assessment of patient outcome with the Minnesota Living With Heart Failure Questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>1017</fpage>
          <lpage>25</lpage>
          <issue>4</issue>
          <volume>124</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rector</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Cohn</surname>
              <given-names>JN</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Carvalho VO, Guimar&#227;es GV, Carrara D, Bacal F, Bocchi EA. Valida&#231;&#227;o da vers&#227;o em portugu&#234;s do Minnesota Living with Heart Failure Questionnaire. Arq Bras Cardiol. 2009; 93 (1): 39-44.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Valida&#231;&#227;o da vers&#227;o em portugu&#234;s do Minnesota Living with Heart Failure Questionnaire</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>39</fpage>
          <lpage>44</lpage>
          <issue>1</issue>
          <volume>93</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Carvalho</surname>
              <given-names>VO</given-names>
            </name>
            <name>
              <surname>Guimar&#227;es</surname>
              <given-names>GV</given-names>
            </name>
            <name>
              <surname>Carrara</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bacal</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. ATS Statement. Guidelines for the six- minute walk test. Am J Respir Crit Care Med. 2002; 166 (1): 111-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Guidelines for the six- minute walk test</article-title>
          <source>Am J Respir Crit Care Med</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>111</fpage>
          <lpage>7</lpage>
          <issue>1</issue>
          <volume>166</volume>
          <person-group person-group-type="author">
            <name>
              <surname>ATS Statement</surname>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Andrade J, Brito FS, Vilas-Boas F, Castro I, Oliveira JA, Guimar&#227;es JI, et al. / Sociedade Brasileira de Cardiologia. II Guidelines on ergometric tests of the Brazilian Society of Cardiology. Arq Bras Cardiol. 2002; 78 (Suppl 2): 1-17.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>II Guidelines on ergometric tests of the Brazilian Society of Cardiology</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1</fpage>
          <lpage>17</lpage>
          <volume>78</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Andrade</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Brito</surname>
              <given-names>FS</given-names>
            </name>
            <name>
              <surname>Vilas-Boas</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Castro</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Guimar&#227;es</surname>
              <given-names>JI</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982; 14 (5): 377-81.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Psychophysical bases of perceived exertion</article-title>
          <source>Med Sci Sports Exerc</source>
          <date>
            <year>1982</year>
          </date>
          <fpage>377</fpage>
          <lpage>81</lpage>
          <issue>5</issue>
          <volume>14</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Borg</surname>
              <given-names>GA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Rubim VS, Drumond Neto C, Romeo JL, Monteiro MW. Prognostic value of the six-minute walk test in heart failure. Arq Bras Cardiol. 2006; 86 (2): 120-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic value of the six-minute walk test in heart failure</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>120</fpage>
          <lpage>5</lpage>
          <issue>2</issue>
          <volume>86</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rubim</surname>
              <given-names>VS</given-names>
            </name>
            <name>
              <surname>Drumond Neto</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Romeo</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Monteiro</surname>
              <given-names>MW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Cipriano GJR, Yuri D, Bernardelli GF, Mair V, Buffolo E, Branco JN. Avalia&#231;&#227;o da seguran&#231;a do teste de caminhada dos 6 minutos em pacientes no pr&#233;-transplante card&#237;aco. Arq Bras Cardiol. 2009, 92 (4): 312-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Avalia&#231;&#227;o da seguran&#231;a do teste de caminhada dos 6 minutos em pacientes no pr&#233;-transplante card&#237;aco</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>312</fpage>
          <lpage>9</lpage>
          <issue>4</issue>
          <volume>92</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cipriano</surname>
              <given-names>GJR</given-names>
            </name>
            <name>
              <surname>Yuri</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bernardelli</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Mair</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Buffolo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Branco</surname>
              <given-names>JN</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Andrade JP, Bocchi EA, Braga FGM, Ferreira SMA, Rohde LEP, Oliveira WA, et al. / Sociedade Brasileira de Cardiologia. III Diretriz brasileira de insufici&#234;ncia card&#237;aca cr&#244;nica. Arq Bras Cardiol. 2009; 92 (6 supl.1): 1-71.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>III Diretriz brasileira de insufici&#234;ncia card&#237;aca cr&#244;nica</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>1</fpage>
          <lpage>71</lpage>
          <issue>6</issue>
          <volume>92</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Andrade</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Braga</surname>
              <given-names>FGM</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>SMA</given-names>
            </name>
            <name>
              <surname>Rohde</surname>
              <given-names>LEP</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>WA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Hambrecht R, Fiehn E, Yu J, Niebauer J, Weigi C, Hilbrich L, et al. Effects of endurance training on mitochondrial ultrastructure and fiber type destribution in skeletal muscle of patients with stable chronic heart failure. J Am Coll Cardiol. 1997; 29 (5): 1067-3.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of endurance training on mitochondrial ultrastructure and fiber type destribution in skeletal muscle of patients with stable chronic heart failure</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>1067</fpage>
          <lpage>3</lpage>
          <issue>5</issue>
          <volume>29</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hambrecht</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fiehn</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Niebauer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Weigi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hilbrich</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Gehlbach BK, Geppert E. The pulmonary manifestations of left heart failure. Chest. 2004; 125 (2): 669-82.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The pulmonary manifestations of left heart failure</article-title>
          <source>Chest</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>669</fpage>
          <lpage>82</lpage>
          <issue>2</issue>
          <volume>125</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gehlbach</surname>
              <given-names>BK</given-names>
            </name>
            <name>
              <surname>Geppert</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Schroeder CA, Balfe DL, Khan SS, Mohsenifar Z. Airflow and breathing strategy in congestive heart failure patients during exercise. Respiration. 2003, 70 (2): 137-42.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Airflow and breathing strategy in congestive heart failure patients during exercise</article-title>
          <source>Respiration</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>137</fpage>
          <lpage>42</lpage>
          <issue>2</issue>
          <volume>70</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Schroeder</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Balfe</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Mohsenifar</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Meyer EC, Lorenzi Filho G, Schettino GPP, Carvalho RR. Ventila&#231;&#227;o n&#227;o-invasiva no cardiopata grave. Rev Soc Cardiol Estado de S&#227;o Paulo. 1998; 8 (3): 420-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ventila&#231;&#227;o n&#227;o-invasiva no cardiopata grave</article-title>
          <source>Rev Soc Cardiol Estado de S&#227;o Paulo</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>420</fpage>
          <lpage>7</lpage>
          <issue>3</issue>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Meyer</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Lorenzi Filho</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schettino</surname>
              <given-names>GPP</given-names>
            </name>
            <name>
              <surname>Carvalho</surname>
              <given-names>RR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Furtado EC, Ramos PS, Ara&#250;jo CGS. Medindo a press&#227;o arterial em exerc&#237;cio aer&#243;bico: subs&#237;dios para reabilita&#231;&#227;o card&#237;aca. Arq Bras Cardiol. 2009; 93 (1): 45-52.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Medindo a press&#227;o arterial em exerc&#237;cio aer&#243;bico: subs&#237;dios para reabilita&#231;&#227;o card&#237;aca</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>45</fpage>
          <lpage>52</lpage>
          <issue>1</issue>
          <volume>93</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Furtado</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Ramos</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Ara&#250;jo</surname>
              <given-names>CGS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Yan AT, Bradley TD, Liu PP. The role of continuous positive airway pressure in the treatment of congestive heart failure. Chest. 2001; 120 (5): 1675-85.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The role of continuous positive airway pressure in the treatment of congestive heart failure</article-title>
          <source>Chest</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>1675</fpage>
          <lpage>85</lpage>
          <issue>5</issue>
          <volume>120</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yan</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Bradley</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>PP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Barbas CSV, Bueno MAS, Amato MBP, Hoelz C, Junior MR. Intera&#231;&#227;o cardiopulmonar durante a ventila&#231;&#227;o mec&#226;nica. Rev Soc Cardiol Estado de S&#227;o Paulo. 1998; 8 (3): 406-19.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Intera&#231;&#227;o cardiopulmonar durante a ventila&#231;&#227;o mec&#226;nica</article-title>
          <source>Rev Soc Cardiol Estado de S&#227;o Paulo</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>406</fpage>
          <lpage>19</lpage>
          <issue>3</issue>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Barbas</surname>
              <given-names>CSV</given-names>
            </name>
            <name>
              <surname>Bueno</surname>
              <given-names>MAS</given-names>
            </name>
            <name>
              <surname>Amato</surname>
              <given-names>MBP</given-names>
            </name>
            <name>
              <surname>Hoelz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Junior</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Wittmer VL, Sim&#245;es GM, Sogame LC, Vasquez EC. Effects of continuous positive airway pressure on pulmonary function and exercise tolerance in patients with congestive heart failure. Chest. 2006; 130 (1): 157-63.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of continuous positive airway pressure on pulmonary function and exercise tolerance in patients with congestive heart failure</article-title>
          <source>Chest</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>157</fpage>
          <lpage>63</lpage>
          <issue>1</issue>
          <volume>130</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wittmer</surname>
              <given-names>VL</given-names>
            </name>
            <name>
              <surname>Sim&#245;es</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Sogame</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Vasquez</surname>
              <given-names>EC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Arena R, Myers J, Abella J, Peberdy MA, Bensimhon D, Chase P, et al. Development of a ventilatory classification system in patients with heart failure. Circulation. 2007; 115 (18): 2410-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Development of a ventilatory classification system in patients with heart failure</article-title>
          <source>Circulation</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>2410</fpage>
          <lpage>7</lpage>
          <issue>18</issue>
          <volume>115</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Arena</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Myers</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Abella</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Peberdy</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Bensimhon</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Chase</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Arena R, Myers J, Williams MA, Gulati M, Kligfield P, Balady GJ, et al. Assessment of functional capacity in clinical and research settings: a scientific statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention of the Council on Clinical Cardiology and the Council on Cardiovascular Nursing. Circulation. 2007; 116 (3): 329-43.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Assessment of functional capacity in clinical and research settings: a scientific statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention of the Council on Clinical Cardiology and the Council on Cardiovascular Nursing</article-title>
          <source>Circulation</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>329</fpage>
          <lpage>43</lpage>
          <issue>3</issue>
          <volume>116</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Arena</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Myers</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Gulati</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kligfield</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Balady</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Effect of ventilatory support on functional capacity in patients with heart failure: a pilot study</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Heart failure (HF) is an important public health problem, of which main clinical symptoms are dyspnea and fatigue. Noninvasive ventilatory support has been used as adjuvant therapy in cardiac rehabilitation in order to improve the functional capacity of patients. OBJECTIVE: To evaluate the functional capacity of patients with HF submitted to ventilatory support. METHODS: We evaluated the sociodemographic information, as well as data on quality of life, blood pressure (BP), peripheral oxygen saturation (SpO2), dyspnea, lactate concentration before and after the 6-minute walk test (6MWT) and the distance walked by patients of both sexes with chronic heart failure (CHF), with left ventricular ejection fraction (LVEF) &lt; 45.0% , randomized in two groups: control and CPAP (the group used CPAP - 10 cmH2O for 30 minutes). RESULTS: A total of 12 patients, of which 8 were males, with CHF functional class II and III (NYHA) participated in the study. The patients had mean LVEF of 35.3 &#177; 8.7 and mean age was 46.3 &#177; 10.3 years. When comparing the control group with the CPAP group at the end of the 6th minute, there was a significant difference between the groups regarding SpO2 values (Control: 93.6 &#177; 1.5 % vs CPAP: 96.1&#177;1.8%; p = 0.027), index of dyspnea (Control: 13.1 &#177; 1.16 vs CPAP: 11 &#177; 0.8; p = 0.009), lactate concentration (Control: 3.3 &#177; 0.7 mmol/l vs CPAP: 2.3 &#177; 0.5 mmol/l; p = 0.025) and distance walked at the 6MWT (Control: 420.6 &#177; 73.8 m vs CPAP: 534 &#177; 89.91 m; p = 0.038). CONCLUSION: The previous use of the CPAP had beneficial effects on SpO2, index of dyspnea, lactate concentration, double product and the distance walked at the 6MWT in patients with CHF when performing the 6MWT.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Heart failure</kwd>
        <kwd>cardiac rehabilitation</kwd>
        <kwd>patient care</kwd>
        <kwd>vital capacity</kwd>
        <kwd>respiration, artificial</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p><undefined id="tx-body2"/>Effect of ventilatory support on functional capacity in patients with heart failure: a pilot study</p>
      <p>
        <bold>Eug&#234;nia da Silva Lima; Cristiano Gon&#231;alves Cruz; Fabiane Costa Santos; Mansueto Gomes-Neto; Hugo Souza Bittencourt; Francisco Jos&#233; Farias Borges dos Reis; Roque Aras; Arm&#234;nio Costa Guimar&#227;es; Erenaldo de Souza Rodrigues-Junior</bold>
      </p>
      <p> Faculdade Social da Bahia, Hospital Ana Nery, Salvador, BA - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p><bold>BACKGROUND:</bold> Heart failure (HF) is an important public health problem, of which main clinical symptoms are dyspnea and fatigue. Noninvasive ventilatory support has been used as adjuvant therapy in cardiac rehabilitation in order to improve the functional capacity of patients.</p>
      <p><bold>OBJECTIVE:</bold> To evaluate the functional capacity of patients with HF submitted to ventilatory support.</p>
      <p><bold>METHODS:</bold> We evaluated the sociodemographic information, as well as data on quality of life, blood pressure (BP), peripheral oxygen saturation (SpO<sub>2</sub>), dyspnea, lactate concentration before and after the 6-minute walk test (6MWT) and the distance walked by patients of both sexes with chronic heart failure (CHF), with left ventricular ejection fraction (LVEF) <underline>&lt;</underline> 45.0% , randomized in two groups: control and CPAP (the group used CPAP - 10 cmH<sub>2</sub>O for 30 minutes).</p>
      <p><bold>RESULTS:</bold> A total of 12 patients, of which 8 were males, with CHF functional class II and III (NYHA) participated in the study. The patients had mean LVEF of 35.3 &#177; 8.7 and mean age was 46.3 &#177; 10.3 years. When comparing the control group with the CPAP group at the end of the 6th minute, there was a significant difference between the groups regarding SpO<sub>2</sub> values (Control: 93.6 &#177; 1.5 % <italic>vs</italic> CPAP: 96.1&#177;1.8%; p = 0.027), index of dyspnea (Control: 13.1 &#177; 1.16 <italic>vs</italic> CPAP: 11 &#177; 0.8; p = 0.009), lactate concentration (Control: 3.3 &#177; 0.7 mmol/l <italic>vs</italic> CPAP: 2.3 &#177; 0.5 mmol/l; p = 0.025) and distance walked at the 6MWT (Control: 420.6 &#177; 73.8 m <italic>vs</italic> CPAP: 534 &#177; 89.91 m; p = 0.038).</p>
      <p><bold>CONCLUSION:</bold> The previous use of the CPAP had beneficial effects on SpO<sub>2</sub>, index of dyspnea, lactate concentration, double product and the distance walked at the 6MWT in patients with CHF when performing the 6MWT.</p>
      <p><bold>Keywords:</bold> Heart failure; cardiac rehabilitation; patient care; vital capacity; respiration, artificial.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Heart failure (HF) is an important public health problem<sup>1</sup>, of which dyspnea and fatigue during physical exercise or activities of daily living are the main clinical symptoms. It is the leading cause of early interruption of physical activity, resulting in restrictions of the daily activities and consequent limitation in functional capacity<sup>2,3</sup>. </p>
      <p>The progression of HF symptoms generates a decrease in the level of physical activity, resulting in the lack of physical conditioning, which contributes to further increase symptoms and exercise intolerance, progressively decreasing functional capacity, which causes a frequent, high-cost, generally incapacitating clinical condition that has a high mortality rate<sup>4</sup>.</p>
      <p>In the cardiac rehabilitation (CR) scenario, the individual's physical conditioning is the objective, aiming at improving the functional capacity and promoting the return to the work and social activities, where the physical performance is a limiting factor<sup>5,6</sup>. One of the main aggravating factors is the development of acute respiratory failure due to the decrease in lung compliance, which increases the respiratory workload<sup>7</sup>. Such decrease is the result of the circulatory failure caused by the left ventricular (LV) dysfunction, which can cause acute and/or chronic damage to the respiratory function<sup>8</sup>. </p>
      <p>In this scenario, the use of noninvasive ventilatory support (NIVS) has arisen as an adjuvant therapy in cardiac rehabilitation in an attempt to improve the functional capacity of patients, as the NIVS decreases the respiratory workload, improves oxygenation, increases lung compliance associated with the improvement in the ejected volume, due to the increase in the intrathoracic pressure<sup>9</sup>. </p>
      <p>The use of NIVS has been an alternative in the attempt to increase arterial oxygenation and provide better tolerance to physical exercise, due to its significant effect on the cardiorespiratory interaction, resulting in a better cardiac and respiratory response during exercise. However, few studies have taken into account the use of NIVS, associated or not to exercise in HF in the context of CR<sup>10</sup>. </p>
      <p>Therefore, the present study aims to evaluating the functional capacity of patients with HF submitted to NIVS. </p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>We evaluated patients of both sexes, with a diagnosis of CHF (New York Heart Association [NYHA] Functional Class II and III), referred to the Department of Ergospirometry and Cardiovascular Rehabilitation of Hospital Ana Nery - UFBA. The present study included patients with left ventricular ejection fraction (LVEF) <underline>&lt;</underline> 45.0% (determined by echocardiography), aged 18 years or older, conscious and neurologically capable of communication and locomotion. Patients that presented limitations to physical activity due to factors other than exertional dyspnea and fatigue, such as intermittent claudication, lower-limb arthrosis and arthritis, psychiatric disease, orovalvular disease of rheumatic origin, anemia, chronic obstructive pulmonary disease (COPD), any febrile condition or infectious disease and those that presented intolerance to NIVS, were excluded from the study. </p>
      <p>Initially, an interview was carried out for data collection and sample characterization, taking into account the management of HF and among them, gender, body mass index (BMI), blood pressure (BP) and the functional classification according to the NYHA. </p>
      <p>Subsequently, the Minnesota Living with Heart Failure Questionnaire was applied to assess quality of life (QoL), which is a disease-specific tool that evaluates the patient's perception regarding the influence of HF on the physical, socioeconomic and psychological aspects<sup>11</sup>.</p>
      <p>Another important consideration about this tool is its comprehensive format, the fact that it is easy to apply and also the fact that it has been validated for the Brazilian population<sup>12</sup>. The participants answered the 21 items using a 6-point answer scale (0-5). The summary of the total score (global score) can range from 0 to 105; a lower score reflects a better QoL. The scores in the three subscales (dimensions) reflect physical (questions number 2, 3, 4, 5, 6, 7, 12 and 13) and emotional difficulties (questions number 17, 18, 19, 20 and 21) and the other items are associated with financial considerations, side effects of medications and lifestyle (general dimensions). </p>
      <p>Subsequently, the patients were randomly allocated to two groups by drawing lots, by placing blue and red ribbons inside opaque envelopes. Patients that chose an envelope containing a blue ribbon were allocated in the CPAP group, which underwent continuous positive airway pressure (CPAP) at 10 cmH<sub>2</sub>O for 30 minutes, before the six-minute walk test (6MWT) and those that chose the envelopes containing the red ribbon were allocated in the Control group, which was not submitted to CPAP. The patients were not aware of which among them had been submitted to CPAP, as the groups were submitted to the procedures on different days.</p>
      <p>A blood sample was collected from the tip of the index finger of the right hand of the patients, using sterile and disposable lancets (Accu-Chek<sup>TM</sup> Softclix<sup>TM</sup> Pro, Roche, Germany), after a 10-minute rest in the sitting position before the 6MWT (for the CPAP group, before the CPAP was applied) and at the end of the 6<sup>th</sup> minute of the 6MWT for lactate concentration measurement using Accutrend<sup>TM</sup> Lactimeter (Roche, Germany). </p>
      <p>The 6MWT was carried out according to the criteria established by the American Thoracic Society (ATS)<sup>13 </sup>and the guidelines for ergometric evaluation established by the Brazilian Society of Cardiology (SBC)<sup>14</sup>, on a 30-meter long walking course, without follow-up and with the patient receiving only the standardized instructions at every minute. The patients were monitored regarding heart rate (HR, bpm), blood pressure (BP, mmHg), peripheral oxygen saturation (SpO<sub>2</sub>, %), subjective sensation of dyspnea (Borg scale)<sup>15</sup> and the values were recorded at rest and at the 2<sup>nd</sup>, 4<sup>th</sup> and 6<sup>th</sup> minutes. </p>
      <p>The study was approved by the Committee of Ethics in Research of Hospital Ana Nery - UFBA, protocol # 37/09 and all patients that agreed to participate signed the Free and Informed Consent Form. </p>
      <p>Descriptive and frequency statistics were used to analyze the demographic and clinical data; the Shapiro-Wilks test was used for the normality and homogeneity of the variables, using the SPSS (Statistical Package for the Social Sciences) for Windows software package (release 13.0). The Student's <italic>t</italic> test was used to analyze parametric data and for variables with non-parametric distribution. Wilcoxon's test was used to compare the differences of intragroup means. When comparing between the two groups, for parametric data, Student's <italic>t</italic> test was used for independent samples and the Mann-Whitney test was used for the nonparametric ones. The level of significance was set at 5.0%.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>A total of 12 patients with NYHA FC II and III CHF participated in the present study. The patients had a mean LVEF of 35.3 &#177; 8.7 and 8 were males. The mean age was 46.3 &#177; 10.3 years and the mean BMI was 25.1 &#177; 5.5 kg/m<sup>2</sup>. The data of the clinical characterization of the sample is shown in <xref ref-type="table" rid="tab01-body2">Table 1</xref>.</p>
      <table-wrap id="tab01-body2">
        <graphic xlink:href="1678-4170-abc-96-03-0227-00002-gt01-en.jpg"/></table-wrap>
      <p><xref ref-type="table" rid="tab02-body2">Table 2</xref> shows the comparison of the clinical characteristics of the patients per group (Control group <italic>vs</italic>. CPAP group) and no significant difference was observed among the variables studied between the groups. </p>
      <table-wrap id="tab02-body2">
        <graphic xlink:href="1678-4170-abc-96-03-0227-00002-gt02-en.jpg"/></table-wrap>
      <p>In the control group, when the variables at rest when compared to those at the 6<sup>th</sup> minute, a significant difference was observed for the hemodynamic variables (SBP: 126.6 &#177; 8.1 mmHg <italic>vs.</italic> 150 &#177; 8.9 mmHg, with p = 0.003; DBP: 85 &#177; 10.4 mmHg <italic>vs</italic> 105 &#177; 5.4 mmHg, with p = 0.01 and HR: 81.1 &#177; 166.8 bpm <italic>vs</italic> 117.8 &#177; 19.3 bpm, with p = 0.006). The analysis of the respiratory and metabolic variables showed a significant difference regarding SpO<sub>2</sub>: 97.3 &#177; 1% <italic>vs</italic> 93.6 &#177; 1.5%, p = 0.001; dyspnea 7 &#177; 1.26 <italic>vs</italic> 13.1 &#177; 1.16, with p = 0.000 and the lactate concentration: 1.6 &#177; 0.73 mmol/l <italic>vs</italic> 3.3 &#177; 0.7 mmol/l, p = 0.028 (<xref ref-type="table" rid="tab03-body2">Table 3</xref>).</p>
      <table-wrap id="tab03-body2">
        <graphic xlink:href="1678-4170-abc-96-03-0227-00002-gt03-en.jpg"/></table-wrap>
      <p>When comparing the variables at rest with those at the 6<sup>th</sup> minute in the CPAP group, there was also a significant difference regarding the hemodynamic data (SBP: 120 &#177; 15.4 mmHg <italic>vs.</italic> 140 &#177; 12.6 mmHg, with p = 0.001; DBP: 76.6 &#177; 8.1 mmHg <italic>vs</italic> 101.6 &#177; 13.2 mmHg, with p = 0.002 and HR: 73.1 &#177; 7.6 bpm <italic>vs</italic> 99.6 &#177; 13 bpm, with p = 0.001). The analysis of respiratory and metabolic variables showed that there was a significant difference regarding dyspnea 6.6 &#177; 0.8 <italic>vs</italic> 11 &#177; 0.8, with p = 0.001 and lactate concentration: 1.1 &#177; 0.2 mmol/l <italic>vs</italic> 2.3 &#177; 0.5 mmol/l, p = 0.028. However, the analysis of SpO<sub>2</sub>, did not show a significant difference between the Rest period and the 6<sup>th</sup> minute (97.5 &#177; 1.0% <italic>vs</italic> 96.1 &#177; 1.8%, p = 0.286), as shown in <xref ref-type="table" rid="tab04-body2">Table 4</xref>.</p>
      <table-wrap id="tab04-body2">
        <graphic xlink:href="1678-4170-abc-96-03-0227-00002-gt04-en.jpg"/></table-wrap>
      <p>The comparative analysis between the groups at the end of the 6<sup>th</sup> minute showed a significant difference in the values of SpO<sub>2</sub>% (Control: 93.6 &#177; 1.5 % <italic>vs</italic> CPAP: 96.1 &#177; 1.8%; p = 0.027), dyspnea (Control: 13.1 &#177; 1.16 <italic>vs</italic> CPAP: 11 &#177; 0.8; p = 0.009), lactate concentration (Control: 3.3 &#177; 0.7 mmol/l <italic>vs</italic> CPAP: 2.3 &#177; 0.5 mmol/l; p = 0.025), double-product (Control: 17,758.3 &#177; 3,623 mmHg.bpm <italic>vs</italic> CPAP: 14,035 &#177; 2,859 mmHg.bpm; p = 0,038) and the distance walked at the 6MWT (Control: 420.6 &#177; 73.8 m <italic>vs</italic> CPAP: 534 &#177; 89.91 m; p = 0.038).</p>
      <p>Moreover, a difference regarding the hemodynamic data was observed, albeit without statistical significance, as shown in <xref ref-type="table" rid="tab05-body2">Table 5</xref>. </p>
      <table-wrap id="tab05-body2">
        <graphic xlink:href="1678-4170-abc-96-03-0227-00002-gt05-en.jpg"/></table-wrap>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>The present study shows that the patients submitted to NIVS obtained better results, as demonstrated by the longer distance walked at the 6MWT and consequent better functional capacity<sup>16</sup>. </p>
      <p>HF presents systemic consequences that directly affect patient functional capacity and, consequently, the activities of daily living, as well as the QoL<sup>17</sup>. This has been corroborated by the results of the present study. </p>
      <p>Cardiac rehabilitation (CR) is considered a set of multidisciplinary therapeutic actions that aim at better clinical evolution, from the physical and psychosocial point of view. During the rehabilitation process, the patients perform several exercises under the supervision of a multiprofessional team. Walking is among the main exercises performed during the treatment of these patients, of which main characteristic is the fact that it is easy to understand and perform on the part of the patients<sup>18</sup>. </p>
      <p>Walking is a physical activity that is limited in patients with HF due to several clinical factors, such as the loss of type I fibers in the skeletal musculature, muscle atrophy, previous hemodynamic condition and metabolic abnormalities<sup>19</sup>. </p>
      <p>Moreover, recent studies have demonstrated the involvement of the respiratory function, with the decrease in the respiratory muscle strength, pulmonary congestion, increase in pulmonary resistance with airflow limitation and ventilation process impairment<sup>20</sup>. </p>
      <p>Schroeder et al<sup>21</sup>, in 2003, evaluated the level of airflow limitation in healthy individuals and patients with HF. That study showed an airflow limitation at rest in patients with HF, which was further exacerbated during physical exercise performance. </p>
      <p>As the NIVS uses positive pressure, it can optimize the cardiac and respiratory function of patients with HF. The positive pressure decreases the large variations in the pleural pressure and, consequently, reduces the transmural pressure of the LV, improving the contractile performance of the heart<sup>22</sup>. </p>
      <p>The data did not show, regarding the hemodynamic parameters (SBP, DBP and HR), significant effects of the previous performance of the positive pressure, in comparison with the Control group at the end of the 6<sup>th</sup> minute. That might be due to the fact that, during the exercise, the patients were no longer using the positive pressure<sup>23</sup>. However, at the assessment of the double-product at the end of the exercise, lower values of this physiological parameter were observed in the group of patients submitted to NIVS. That leads us to believe that the NIVS can previously improve the performance of the cardiovascular and respiratory systems, so that during the 6MWT performance, such patients presented a lower cardiac workload<sup>22</sup>. </p>
      <p>In agreement with the findings of the present study, Chermont et al<sup>10</sup> studied 12 patients, divided in two groups, placebo and CPAP for 30 minutes before the 6MWT. That study showed no significant alterations regarding the SBP, DBP and mean arterial pressure (MAP). </p>
      <p>Regarding the pulmonary function, as the positive pressure decreases the airway resistance in patients with HF, it increases lung compliance, improves gas exchange, decreases the respiratory workload and reduces airflow limitation<sup>24</sup>. Similarly, our results showed that the previous use of CPAP for 30 minutes optimized the patients' pulmonary function in such a way that they, at the end of the 6<sup>th</sup> minute of walking, did not present a significant desaturation. </p>
      <p>The comparative analysis of the studied parameters at the end of the 6<sup>th</sup> minute showed a higher level of SpO<sub>2 </sub>and a lower index of dyspnea in the group previously submitted to CPAP, showing that the beneficial effects of the positive pressure on the pulmonary function of patients with HF persisted until the end of the exercise proposed in this study. Such results demonstrate the capacity of the noninvasive ventilation to improve the pulmonary function parameters and, therefore, allow the more effective performance of the exercise.</p>
      <p>Barbas et al<sup>25</sup> reported on the beneficial effects of the positive pressure on the pulmonary function of patients with cardiopathy, with a decrease in pulmonary congestion and improved gas exchange. </p>
      <p>Witmmer et al<sup>26</sup> used daily CPAP sessions for 30 minutes before exercise performance in patients with HF for two weeks and observed an improvement in pulmonary function and the distance walked by the patients that used the CPAP, in agreement with the findings of the present study. </p>
      <p>The simplified analysis of the lactate concentrations showed that the patients submitted to NIVS exhibited lower lactate concentrations, suggesting a lower utilization of the anaerobic metabolism. Current scientific evidence demonstrates the association between the anaerobic metabolism and the functional capacity as an important predictor of mortality<sup>27,28</sup>.</p>
      <p>The present study showed some limitations. Initially, it was not possible to define the duration of the effects that were verified, as the administration of the NIVS was interrupted for the performance of the 6MWT. It would be important to determine whether several sessions with NIVS could maintain the effect for a longer period of time and whether these effects are associated with clinical improvement.</p>
      <p>Therefore, the continuity of the present study with a larger sample size, as well as other studies on the same subject, is necessary to elucidate the effects of NIVS as a new alternative in therapeutic support for the CR of patients with HF. </p>
      <p>
        <bold>Conclusion</bold>
      </p>
      <p>The previous use of CPAP with 10 cmH<sub>2</sub>O for 30 minutes presented beneficial effects on SpO<sub>2</sub>, dyspnea index, lactate concentration, double-product and the distance walked by patients with CHF when performing the 6MWT. However, the results of the present study must be taken into account cautiously, as it is a pilot-study carried out with a small sample size. </p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Soporte ventilatorio en la capacidad funcional de pacientes con insuficiencia cardiaca: estudio piloto</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: La insuficiencia cardiaca es un importante problema de salud p&#250;blica, presentando la disnea y la fatiga como principales s&#237;ntomas cl&#237;nicos. La utilizaci&#243;n del soporte ventilatorio no invasivo viene actuando como coadyuvante de la rehabilitaci&#243;n card&#237;aca en la tentativa de mejorar la capacidad funcional de los pacientes. OBJETIVO: Evaluar la capacidad funcional de pacientes con insuficiencia cardiaca sometidos al soporte ventilatorio. M&#201;TODOS: Se evaluaron datos sociodemogr&#225;ficos, calidad de vida, FC, presi&#243;n arterial (PA), saturaci&#243;n perif&#233;rica de ox&#237;geno (SpO2) disnea, concentraci&#243;n de lactato, antes y despu&#233;s de la prueba de marcha de 6 minutos, y la distancia recorrida de pacientes con insuficiencia cardiaca cr&#243;nica (ICC), de ambos sexos, con fracci&#243;n FEVI &lt; 45,0%, randomizados en dos grupos: Control y CPAP (utiliz&#243; CPAP 10 cmH2O por 30 minutos). RESULTADOS: Participaron 12 pacientes con ICC clase funcional II y III (NYHA), con media de fracci&#243;n de eyecci&#243;n del ventr&#237;culo izquierdo (FEVI, %) de 35,3 &#177; 8,7, siendo que 8 eran del sexo masculino. El promedio de edad fue de 46,3 &#177; 10,3 a&#241;os. En la comparaci&#243;n entre los grupos control y CPAP, al final del 6&#186; min, se encontr&#243; diferencia significativa en los valores de SpO2% entre los grupos (Control: 93,6 &#177; 1,5 % vs CPAP: 96,1 &#177; 1,8%; p = 0,027), disnea (Control: 13,1 &#177; 1,16 vs CPAP: 11 &#177; 0,8; p = 0,009), concentraci&#243;n de lactato (Control: 3,3 &#177; 0,7 mmol/L vs CPAP: 2,3 &#177; 0,5 mmol/L; p = 0,025), y distancia recorrida en la PM6m (Control: 420,6 &#177; 73,8 m vs CPAP: 534 &#177; 89,91 m; p = 0,038). CONCLUSI&#211;N: La realizaci&#243;n previa del CPAP present&#243; efectos ben&#233;ficos en la SpO2, en la disnea, en la concentraci&#243;n de lactato, en el doble producto y en la distancia recorrida en el PM6m de pacientes con ICC en la realizaci&#243;n del PM6m.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Insuficiencia card&#237;aca</kwd>
        <kwd>rehabilitaci&#243;n card&#237;aca</kwd>
        <kwd>atenci&#243;n al paciente</kwd>
        <kwd>capacidad vital</kwd>
        <kwd>respiraci&#243;n artificial</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p>
        <fn id="enda-body3">
          <label>
            <bold>Soporte ventilatorio en la capacidad funcional de pacientes con insuficiencia cardiaca: estudio piloto</bold>
          </label>
          <p>
            <bold>Eug&#234;nia da Silva lima; Cristiano Gon&#231;alves Cruz; Fabiane Costa Santos; Mansueto Gomes-Neto; Hugo Souza Bittencourt; Francisco Jos&#233; Farias Borges dos Reis; Roque Aras; Arm&#234;nio Costa Guimar&#227;es; Erenaldo de Souza Rodrigues-Junior </bold>
          </p>
        </fn>
      </p>
      <p>Faculdade Social da Bahia, Hospital Ana Nery, Salvador, BA - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO:</bold> La insuficiencia cardiaca es un importante problema de salud p&#250;blica, presentando la disnea y la fatiga como principales s&#237;ntomas cl&#237;nicos. La utilizaci&#243;n del soporte ventilatorio no invasivo viene actuando como coadyuvante de la rehabilitaci&#243;n card&#237;aca en la tentativa de mejorar la capacidad funcional de los pacientes. </p>
      <p><bold>OBJETIVO:</bold> Evaluar la capacidad funcional de pacientes con insuficiencia cardiaca sometidos al soporte ventilatorio. </p>
      <p><bold>M&#201;TODOS:</bold> Se evaluaron datos sociodemogr&#225;ficos, calidad de vida, FC, presi&#243;n arterial (PA), saturaci&#243;n perif&#233;rica de ox&#237;geno (SpO<sub>2</sub>) disnea, concentraci&#243;n de lactato, antes y despu&#233;s de la prueba de marcha de 6 minutos, y la distancia recorrida de pacientes con insuficiencia cardiaca cr&#243;nica (ICC), de ambos sexos, con fracci&#243;n FEVI <underline>&lt;</underline> 45,0%, randomizados en dos grupos: Control y CPAP (utiliz&#243; CPAP 10 cmH<sub>2</sub>O por 30 minutos). </p>
      <p><bold>RESULTADOS:</bold> Participaron 12 pacientes con ICC clase funcional II y III (NYHA), con media de fracci&#243;n de eyecci&#243;n del ventr&#237;culo izquierdo (FEVI, %) de 35,3 &#177; 8,7, siendo que 8 eran del sexo masculino. El promedio de edad fue de 46,3 &#177; 10,3 a&#241;os. En la comparaci&#243;n entre los grupos control y CPAP, al final del 6&#186; min, se encontr&#243; diferencia significativa en los valores de SpO2% entre los grupos (Control: 93,6 &#177; 1,5 % vs CPAP: 96,1 &#177; 1,8%; p = 0,027), disnea (Control: 13,1 &#177; 1,16 vs CPAP: 11 &#177; 0,8; p = 0,009), concentraci&#243;n de lactato (Control: 3,3 &#177; 0,7 mmol/L vs CPAP: 2,3 &#177; 0,5 mmol/L; p = 0,025), y distancia recorrida en la PM6m (Control: 420,6 &#177; 73,8 m vs CPAP: 534 &#177; 89,91 m; p = 0,038). </p>
      <p><bold>CONCLUSI&#211;N: </bold>La realizaci&#243;n previa del CPAP present&#243; efectos ben&#233;ficos en la SpO<sub>2</sub>, en la disnea, en la concentraci&#243;n de lactato, en el doble producto y en la distancia recorrida en el PM6m de pacientes con ICC en la realizaci&#243;n del PM6m. </p>
      <p><bold>Palabras clave:</bold> Insuficiencia card&#237;aca, rehabilitaci&#243;n card&#237;aca, atenci&#243;n al paciente, capacidad vital, respiraci&#243;n artificial. </p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La insuficiencia cardiaca (IC) se constituye actualmente un importante problema de salud p&#250;blica<sup>1</sup>, presentando la disnea y la fatiga durante el ejercicio o actividades de vida diaria como principales s&#237;ntomas cl&#237;nicos, siendo la mayor causa para los pacientes interrumpir el esfuerzo f&#237;sico precozmente, ocasionando restricci&#243;n de las actividades cotidianas y consecuente limitaci&#243;n en la capacidad funcional<sup>2, 3</sup>. </p>
      <p>La progresi&#243;n de los s&#237;ntomas de la IC genera una disminuci&#243;n del nivel de actividad f&#237;sica, provocando el descondicionamiento f&#237;sico, que contribuye a elevar a&#250;n m&#225;s los s&#237;ntomas y la intolerancia al ejercicio, reduciendo progresivamente la capacidad funcional, lo que conlleva una condici&#243;n cl&#237;nica frecuente, de alto costo, generalmente incapacitante y con mortalidad elevada<sup>4</sup>. </p>
      <p>En el &#225;mbito de la rehabilitaci&#243;n card&#237;aca (RC), se busca el condicionamiento del individuo, y tiene por objeto la mejora de la capacidad funcional y el retorno a las actividades de trabajo y sociales, en las que el desempe&#241;o f&#237;sico es un factor limitante<sup>5,6</sup>. Uno de los principales empeoramientos es el desarrollo de la insuficiencia respiratoria aguda debido a la reducci&#243;n de la complacencia pulmonar que aumenta el trabajo respiratorio<sup>7</sup>. Dicha reducci&#243;n es resultado de la insuficiencia circulatoria ocasionada por la disfunci&#243;n del ventr&#237;culo izquierdo (VI), que puede ocasionar perjuicios agudos y/o cr&#243;nicos en la funci&#243;n respiratoria<sup>8</sup>. </p>
      <p>En este escenario, surge la utilizaci&#243;n del suporte ventilatorio no invasivo (SVNI) como coadyuvante de la rehabilitaci&#243;n card&#237;aca en la tentativa de mejorar la capacidad funcional de los pacientes, una vez que el SVNI reduce el trabajo respiratorio, mejora la oxigenaci&#243;n, aumenta a complacencia pulmonar asociada a mejora del volumen eyecci&#243;n, debido al aumento de la presi&#243;n intrator&#225;cica<sup>9</sup>. </p>
      <p>La utilizaci&#243;n del SVNI ha sido una alternativa en la tentativa de aumentar la oxigenaci&#243;n arterial y proporcionar una mejor tolerancia durante el ejercicio f&#237;sico debido a su sensible actuaci&#243;n en la interacci&#243;n cardiorrespiratoria, proporcionando una mejor respuesta card&#237;aca y respiratoria durante el ejercicio. Sin embargo, son raros los estudios que llevan en consideraci&#243;n la utilizaci&#243;n del SVNI asociado o no al ejercicio en la IC en el marco de la RC<sup>10</sup>. </p>
      <p>Siendo as&#237;, la propuesta del presente estudio se evalu&#243; la capacidad funcional de pacientes con IC sometidos al SVNI. </p>
      <p>
        <bold>Metodolog&#237;a </bold>
      </p>
      <p>Se evaluaron a pacientes de ambos sexos, con diagn&#243;stico de ICC (clase funcional II y III de la <italic>New York Heart Association - NYHA</italic>) remitidos para el sector de Ergoespirometr&#237;a y Rehabilitaci&#243;n Cardiovascular del Hospital Ana Nery - UFBA. En este estudio, se incluyeron a pacientes con fracci&#243;n de eyecci&#243;n del ventr&#237;culo izquierdo (FEVI) <underline>&lt;</underline> 45,0% (determinado por ecocardiograf&#237;a), edad superior a 18 a&#241;os, conscientes y neurol&#243;gicamente capaces de comunicarse y desplazarse. Se excluyeron a los pacientes que presentaron limitaci&#243;n de la actividad f&#237;sica por factores diferentes de disnea de esfuerzo y fatiga, tales como claudicaci&#243;n intermitente, artrosis y artritis de miembros inferiores, enfermedad siqui&#225;trica, enfermedad orovalvular reum&#225;tica, anemia, enfermedad pulmonar obstructiva cr&#243;nica (EPOC), cualquier estado febril o enfermedad infecciosa, o que presentara intolerancia al SVNI. </p>
      <p>Inicialmente, se llev&#243; a cabo una entrevista para la recolecci&#243;n de datos de la caracterizaci&#243;n de la muestra tomando en consideraci&#243;n el manejo de la IC, entre ellos el g&#233;nero, &#237;ndice de masa corporal (IMC), presi&#243;n arterial (PA) y la clasificaci&#243;n funcional de acuerdo con la <italic>NYHA</italic>. </p>
      <p> En la secuencia, se aplic&#243; el cuestionario para la verificaci&#243;n de la calidad de vida (CV) Minnesota (<italic>Minnesota Living with Heart Failure Questionnaire</italic>), una medici&#243;n enfermedad-espec&#237;fica que eval&#250;a las percepciones de los pacientes sobre la influencia de la IC en los aspectos f&#237;sicos, socioecon&#243;micos y sicol&#243;gicos<sup>11</sup>. </p>
      <p>Otra importante consideraci&#243;n sobre este instrumento es su formato abarcante, f&#225;cil de aplicar y el hecho de haber sido validado para la poblaci&#243;n brasile&#241;a<sup>12</sup>. Los participantes respondieron los 21 &#237;tems utilizando una escala de respuesta de 6 puntos (0-5). El resumen del score total (score global) puede variar de 0 a 105; un score m&#225;s bajo refleja mejor CV. Los scores en las tres subescalas (dimensiones) reflejan dificultades f&#237;sicas (cuestiones n&#186;. 2, 3, 4, 5, 6, 7, 12 y 13), emocionales (cuestiones n&#186;. 17, 18, 19, 20 y 21) y los otros &#237;tems est&#225;n relacionados con consideraciones financieras, efectos colaterales de medicamentos y estilo de vida (dimensiones generales). </p>
      <p>Posteriormente, se asignaron a los pacientes en dos grupos de forma randomizada por sorteo, donde se colocaron tarjas azules y rojas en sobres opacos. Los pacientes que reactivaron el sobre con franja azul se asignar&#237;an en el grupo CPAP, que realiz&#243; la aplicaci&#243;n de CPAP la 10 cmH<sub>2</sub>O por 30 minutos, antes de la prueba de marcha de 6 minutos (PM6m), y los que retiraron franja roja fueron asignados en el grupo control, que no llev&#243; a cabo CPAP. Los pacientes no ten&#237;an conocimiento de qui&#233;n hab&#237;a realizado CPAP, ya que los grupos realizaban los procedimientos en d&#237;as distintos. </p>
      <p>Se recolect&#243; una muestra de sangre capilar del dedo indicador de la mano derecha del examinado, con las lancetas est&#233;riles y desechables de la marca Accu-Chek<sup>&#174;</sup> Softclix<sup>&#174;</sup> Pro (Roche, Alemania), tras 10 minutos de reposo en la posici&#243;n sentada antes de la PM6m (para el grupo CPAP, antes de la realizaci&#243;n de la CPAP) y en el final del 6&#186; minuto de la PM6m, y dosificado su concentraci&#243;n de lactato utilizando el Lact&#237;metro Accutrend<sup>&#174;</sup> (Roche, Alemania). </p>
      <p> La PM6m se llev&#243; a cabo de acuerdo con los criterios establecidos por la <italic>American Toracic Society</italic> (<italic>ATS</italic>)<sup>13 </sup>y las directrices para la realizaci&#243;n de ex&#225;menes ergom&#233;tricos de la Sociedad Brasile&#241;a de Cardiolog&#237;a (SBC)<sup>14</sup>, en pista de 30 metros de longitud, sin seguimiento y recibiendo solamente las orientaciones estandarizadas a cada minuto. Los pacientes se monitorearon en cuanto a la frecuencia cardiaca (FC, lpm), presi&#243;n arterial (PA, mmHg), saturaci&#243;n perif&#233;rica de ox&#237;geno (SpO<sub>2</sub>, %), sensaci&#243;n subjetiva de disnea (escala de Borg)<sup>15</sup>, siendo registrados los valores de reposo y en los 2&#186;, 4&#186; y 6&#186; minutos. </p>
      <p>La investigaci&#243;n cont&#243; con el previo consentimiento de los pacientes y fue aprobada por el Comit&#233; de &#201;tica e Investigaci&#243;n del Hospital Ana Nery - UFBA, bajo dictamen n&#186; 37/09. </p>
      <p>Para el an&#225;lisis de los datos demogr&#225;ficos y cl&#237;nicos, se utilizaron estad&#237;sticas descriptivas y de frecuencia; para la normalidad y homogeneidad de las variables se utiliz&#243; la prueba de Shapiro-Wilk con la utilizaci&#243;n del software <italic>SPSS</italic> (<italic>Statistical Package for the Social Sciences</italic>) <italic>for Windows</italic> (versi&#243;n 13.0). La prueba t de <italic>Student</italic> se utiliz&#243; para los datos param&#233;tricos y para las variables con distribuci&#243;n no param&#233;trica. La prueba Wilcoxon se utiliz&#243; para comparar las diferencias de los promedios intragrupos. En la comparaci&#243;n entre los grupos, se utilizaron para los datos param&#233;tricos la prueba t de <italic>Student</italic> para muestras independientes y la prueba de Mann-Whitney para los datos no param&#233;tricos. Se estableci&#243; un nivel de significancia de un 5%. </p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>Participaron en este estudio 12 pacientes con ICC clase funcional II y III NYHA, con media de FEVI% de 35,3 &#177; 8,7, siendo 8 del sexo masculino. El promedio de edad fue de 46,3 &#177; 10,3 a&#241;os y fue el IMC de 25,1 &#177; 5,5 Kg/m<sup>2</sup>. Los datos de la caracterizaci&#243;n cl&#237;nica de los sujetos estudiados est&#225;n presentados en la <xref ref-type="table" rid="tab1-body3">Tabla 1</xref>. </p>
      <table-wrap id="tab1-body3">
        <graphic xlink:href="1678-4170-abc-96-03-0227-00002-gt01-es.jpg"/></table-wrap>
      <p>La <xref ref-type="table" rid="tab2-body3">Tabla 2</xref> presenta la comparaci&#243;n de las caracter&#237;sticas cl&#237;nicas de los pacientes por grupo (grupo Control <italic>vs</italic> grupo CPAP), donde no se observ&#243; diferencia significativa para las variables estudiadas entre los grupos. </p>
      <table-wrap id="tab2-body3">
        <graphic xlink:href="1678-4170-abc-96-03-0227-00002-gt02-es.jpg"/></table-wrap>
      <p>En el grupo control, cuando comparada las variables en reposo con el 6&#186; minuto, se observ&#243; una diferencia significativa para las variables hemodin&#225;micas (PAS 126,6 &#177; 8,1 mmHg <italic>vs</italic> 150 &#177; 8,9 mmHg, con p = 0,003; PAD 85 &#177; 10,4 mmHg <italic>vs</italic> 105 &#177; 5,4 mmHg, con p = 0,01 y FC 81,1 &#177; 166,8 lpm <italic>vs</italic> 117,8 &#177; 19,3 lpm, con p = 0,006). En el an&#225;lisis de las variables respiratorias y metab&#243;licas, se observ&#243; una diferencia significativa en SpO<sub>2</sub> 97,3 &#177; 1% <italic>vs</italic> 93,6 &#177; 1,5%, p = 0,001; disnea 7 &#177; 1,26 <italic>vs</italic> 13,1 &#177; 1,16, con p = 0,000 y la concentraci&#243;n de lactato 1,6 &#177; 0,73 mmol/L <italic>vs</italic> 3,3 &#177; 0,7 mmol/L, p = 0,028 (<xref ref-type="table" rid="tab3-body3">Tabla 3</xref>). </p>
      <table-wrap id="tab3-body3">
        <graphic xlink:href="1678-4170-abc-96-03-0227-00002-gt03-es.jpg"/></table-wrap>
      <p>Cuando comparada las variables en reposo con el 6&#186; minuto en el grupo CPAP, se observ&#243; tambi&#233;n una diferencia significativa para las variables en los datos hemodin&#225;micos (PAS 120 &#177; 15,4 mmHg vs 140 &#177; 12,6 mmHg, con p = 0,001; PAD 76,6 &#177; 8,1 mmHg vs 101,6 &#177; 13,2 mmHg, con p = 0,02 y FC 73,1 &#177; 7,6 lpm vs 99,6 &#177; 13 lpm, con p = 0,001). En el an&#225;lisis de las variables respiratorias y metab&#243;licas, se observ&#243; una diferencia significativa en disnea 6,6 &#177; 0,8 vs 11 &#177; 0,08, con p = 0,001 y en la concentraci&#243;n de Lactato 1,1 &#177; 0,2 mmol/L vs 2,3 &#177; 0,5 mmol/L, p = 0,028. Sin embargo, en la evaluaci&#243;n de la SpO2 no se observ&#243; diferencia entre el momento en reposo y el 6&#186; min (97,5 &#177; 1,% <italic>vs</italic> 96,1 &#177; 1,8%, p = 0,286), seg&#250;n la <xref ref-type="table" rid="tab4-body3">Tabla 4</xref>. </p>
      <table-wrap id="tab4-body3">
        <graphic xlink:href="1678-4170-abc-96-03-0227-00002-gt04-es.jpg"/></table-wrap>
      <p>En el an&#225;lisis comparativo entre los grupos Control y CPAP, al final del 6&#186; min, se encontr&#243; diferencia significativa en los valores de SpO<sub>2</sub>% entre los grupos (Control: 93,6 &#177; 1,5 % <italic>vs</italic> CPAP: 96,1 &#177; 1,8%; p = 0,027), disnea (Control: 13,1 &#177; 1,16 <italic>vs</italic> CPAP: 11 &#177; 0,8; p = 0,009), concentraci&#243;n de lactato (Control: 3,3 &#177; 0,7 mmol/L <italic>vs</italic> CPAP: 2,3 &#177; 0,5 mmol/L; p = 0,025), doble-producto (Control: 17.758,3 &#177; 3.623 mmHg.lpm <italic>vs</italic> CPAP: 14.035 &#177; 2.859 mmHg.lpm; p = 0,038) y distancia recorrida en la PM6m (Control: 420,6 &#177; 73,8 m <italic>vs</italic> CPAP: 534 &#177; 89,91 m; p = 0,038). </p>
      <p>Se observ&#243; a&#250;n una diferencia en los datos hemodin&#225;micos, sin embargo, sin significancia estad&#237;stica, se conforme con la <xref ref-type="table" rid="tab5-body3">Tabla 5</xref>. </p>
      <table-wrap id="tab5-body3">
        <graphic xlink:href="1678-4170-abc-96-03-0227-00002-gt05-es.jpg"/></table-wrap>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>Por medio del presente estudio, podemos observar que los pacientes sometidos al SVNI obtuvieron mejores resultados, resaltando una mayor distancia recorrida en la PM6m y consecuente mejor capacidad funcional<sup>16</sup>. </p>
      <p>La IC presenta consecuencias multisist&#233;micas que afectan directamente la capacidad funcional de los pacientes y, consecuentemente, sus actividades de la vida diaria, as&#237; como su CV<sup>17</sup>. Esto fue corroborado con los resultados del presente estudio. </p>
      <p>La RC es considerada un conjunto de terap&#233;uticas multidisciplinares que objetivan la mejor evoluci&#243;n cl&#237;nica, desde el punto de vista f&#237;sico y sicosocial. Durante el proceso de rehabilitaci&#243;n, los pacientes llevan a cabo diversos ejercicios bajo la supervisi&#243;n del equipo multiprofesional. Entre los principales ejercicios realizados en el tratamiento de estos pacientes, tenemos la caminata, que presenta, como principal caracter&#237;stica, su f&#225;cil comprensi&#243;n y realizaci&#243;n por parte de los pacientes<sup>18</sup>. </p>
      <p>La realizaci&#243;n de la caminata es limitada en los pacientes portadores de IC por diversos factores cl&#237;nicos, como por ejemplo la p&#233;rdida de fibras tipo I en la musculatura esquel&#233;tica, hipotrofia muscular, condici&#243;n hemodin&#225;mica previa y anormalidades metab&#243;licas<sup>19</sup>. Adem&#225;s de esto, trabajos recientes vienen mostrando los compromisos en la funci&#243;n respiratoria, como disminuci&#243;n de la fuerza muscular respiratoria, congesti&#243;n pulmonar, aumento de la resistencia pulmonar con limitaci&#243;n al flujo de aire y perjuicio en el proceso de la ventilaci&#243;n<sup>20</sup>. </p>
      <p>Schroeder et al<sup>21</sup>, evaluaron el nivel de limitaci&#243;n al flujo a&#233;reo en individuos sanos y en pacientes con IC. En este trabajo, se encontr&#243; una limitaci&#243;n al flujo a&#233;reo en reposo en los pacientes con IC, que fue todav&#237;a m&#225;s exacerbada durante la realizaci&#243;n del ejercicio. </p>
      <p>El SVNI, por utilizar presi&#243;n positiva, logra optimizar la funci&#243;n card&#237;aca y respiratoria de los pacientes con IC. La presi&#243;n positiva disminuye las grandes variaciones en la presi&#243;n pleural y, consecuentemente, reduce la presi&#243;n transmural del VI, mejorando el desempe&#241;o contr&#225;ctil del coraz&#243;n<sup>22</sup>. </p>
      <p>A trav&#233;s de los datos, no evidenciamos en los par&#225;metros hemodin&#225;micos (PAS, PAD y FC) efectos significativos de la realizaci&#243;n previa de la presi&#243;n positiva, en comparaci&#243;n con el grupo control al final del 6&#186; minuto. Dicha condici&#243;n tal vez se deba al hecho de que, durante la realizaci&#243;n del ejercicio, los pacientes no hac&#237;an m&#225;s uso de la presi&#243;n positiva<sup>23</sup>. Sin embargo, en la evaluaci&#243;n del doble-producto al final del ejercicio, encontramos menores valores de este par&#225;metro fisiol&#243;gico en el grupo de pacientes que hicieron uso del SVNI. Esta condici&#243;n nos lleva a creer que el SVNI logra mejorar previamente el desempe&#241;o del sistema cardiovascular y del sistema respiratorio de tal manera que, durante la realizaci&#243;n del PM6m, tales pacientes presentaban un menor trabajo card&#237;aco<sup>22</sup>. </p>
      <p>Concordando con los hallazgos del presente estudio, Chermont et al<sup>10</sup>, estudiaron a 12 pacientes, divididos en grupo placebo y grupo CPAP por 30 minutos antes de la realizaci&#243;n del PM6m. En este estudio, los autores no encontraron alteraciones significantes en los datos de PAS, PAD y presi&#243;n arterial media (PAM). </p>
      <p>Sin embargo, con relaci&#243;n a la funci&#243;n pulmonar, por disminuir la resistencia de v&#237;a a&#233;rea en los pacientes con IC, la presi&#243;n positiva aumenta la complacencia pulmonar, mejora el intercambio gaseoso, disminuye el trabajo respiratorio y reduce la limitaci&#243;n al flujo a&#233;reo<sup>24</sup>. En el mismo sentido, los nuestros resultados revelaron que la realizaci&#243;n previa del CPAP por 30 minutos optimiz&#243; la funci&#243;n pulmonar de los pacientes de tal suerte que estos, al final del 6&#186; minuto de caminata, no presentaron una desaturaci&#243;n significante. </p>
      <p>En el an&#225;lisis comparativo de los par&#225;metros estudiados al final del 6&#186; minuto, observamos un mayor nivel de SpO<sub>2 </sub>y menor &#237;ndice de disnea en el grupo que hizo uso previo del CPAP, mostrando que los efectos ben&#233;ficos de la presi&#243;n positiva, en la funci&#243;n pulmonar de los pacientes con IC, perduraron hasta el final del ejercicio propuesto en este estudio. Dichos resultados demuestran la capacidad de la ventilaci&#243;n no invasiva en mejorar los par&#225;metros de la funci&#243;n pulmonar, y de esta forma, posibilitar la realizaci&#243;n del ejercicio de manera m&#225;s eficaz. </p>
      <p>Barbas et al<sup>25</sup>, relatan los efectos positivos de la presi&#243;n positiva en la funci&#243;n pulmonar de pacientes cardi&#243;patas con disminuci&#243;n de la congesti&#243;n pulmonar y mejora del intercambio gaseoso. </p>
      <p>Witmmer et al<sup>26</sup>, utilizaron diariamente el CPAP por 30 minutos antes de la realizaci&#243;n de ejercicio para pacientes con IC por dos semanas, y se observ&#243; que hubo una mejora en la funci&#243;n pulmonar y en la distancia recorrida de los pacientes que utilizaron CPAP, concordando con los resultados encontrados en el presente estudio. </p>
      <p>Atrav&#233;s del an&#225;lisis simplificado de la concentraci&#243;n de lactato, pudimos constatar que los pacientes sometidos al SVNI obtuvieron menores concentraciones de lactato, sugiriendo una menor utilizaci&#243;n de metabolismo anaer&#243;bico. Evidencias cient&#237;ficas actuales evidencian la relaci&#243;n entre el metabolismo anaer&#243;bico y la capacidad funcional como importante predictor de mortalidad<sup>27,28</sup>. </p>
      <p>El presente estudio present&#243; algunas limitaciones. Inicialmente, no fue posible definir el tiempo de duraci&#243;n de los efectos verificados, una vez que la administraci&#243;n del SVNI fue interrumpida para la realizaci&#243;n del PM6m. Ser&#237;a importante determinar si varias sesiones con el uso del SVNI podr&#237;an ser capaces de mantener el efecto por un tiempo m&#225;s prolongado y si estos efectos est&#225;n asociados con una mejora cl&#237;nica. </p>
      <p>Siendo as&#237;, la continuidad de este estudio, con el incremento de la muestra, as&#237; como la realizaci&#243;n de otras investigaciones en esta tem&#225;tica, se vuelve necesaria para elucidar los efectos del SVNI como una nueva alternativa de soporte terap&#233;utico en la RC de pacientes con IC. </p>
      <p>
        <bold>Conclusi&#243;n</bold>
      </p>
      <p>La realizaci&#243;n previa del CPAP con 10 cmH<sub>2</sub>O por 30 minutos present&#243; efectos ben&#233;ficos en la SpO<sub>2</sub>, en el &#237;ndice de disnea, en la concentraci&#243;n de lactato, en el doble-producto y en la distancia recorrida de pacientes con ICC en la realizaci&#243;n de la PM6m. Sin embargo, estos resultados se deben observar con cautela, ya que esta investigaci&#243;n se trata de un estudio-piloto realizado con una muestra reducida de pacientes. </p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes. </p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuve fuentes de financiaci&#243;n externas. </p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>No hay vinculaci&#243;n de este estudio a programas de postgrado. </p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
